Currently, biomarkers, specifically CSF markers, can be used primarily as a research tool and optionally by physicians to identify at-risk patients for developing Alzheimer’s disease, with some patient stratification strategies considering their progression recently issued.10 The amyloid, tau and neurodegeneration (A/T/N) classification framework has paved the way for better patient stratification with increased risk profiling,11,12 however, we are still lacking high accuracy progression and differentiating markers for Alzheimer’s disease and other dementias. This evidence concerns the gene MAPT and Alzheimer disease.